Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P de Boer

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Blood|January 1, 1993
Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in ratsB J de Smet, J P de Boer, J Agterberg, et al.
Clinical Rheumatology|July 31, 2007
A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphomaF H Swaneveld, R M van Vugt, J P de Boer, et al.
Immunopharmacology|September 1, 1992
Interplay of complement and cytokines in the pathogenesis of septic shockJ P de Boer, G J Wolbink, L G Thijs, et al.
Human Antibodies|May 12, 2011
The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximabL Tran, J W Baars, J P de Boer, et al.
Agents and Actions. Supplements|January 1, 1992
Contact system dependent fibrinolytic activity in vivo: observations in healthy subjects and factor XII deficient patientsM Levi, C E Hack, J P de Boer, et al.
The Journal of Clinical Investigation|October 1, 1991
Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivoM Levi, C E Hack, J P de Boer, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 17, 2020
[Papillary carcinoma in a thyroglossal duct cyst; diagnostics and treatment]M F J van der Heide, L H E Karssemakers, J P de Boer, et al.
Infection and Immunity|October 1, 1993
Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation patternJ P de Boer, A A Creasey, A Chang, et al.
Current Treatment Options in Oncology|November 19, 2013
Current treatment options for local residual nasopharyngeal carcinomaS D Stoker, J N A van Diessen, J P de Boer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2005
Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patientsR L M Haas, Ph Poortmans, D de Jong, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Blood|January 1, 1993
Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in ratsB J de Smet, J P de Boer, J Agterberg, et al.
Clinical Rheumatology|July 31, 2007
A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphomaF H Swaneveld, R M van Vugt, J P de Boer, et al.
Immunopharmacology|September 1, 1992
Interplay of complement and cytokines in the pathogenesis of septic shockJ P de Boer, G J Wolbink, L G Thijs, et al.
Human Antibodies|May 12, 2011
The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximabL Tran, J W Baars, J P de Boer, et al.
Agents and Actions. Supplements|January 1, 1992
Contact system dependent fibrinolytic activity in vivo: observations in healthy subjects and factor XII deficient patientsM Levi, C E Hack, J P de Boer, et al.
The Journal of Clinical Investigation|October 1, 1991
Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivoM Levi, C E Hack, J P de Boer, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 17, 2020
[Papillary carcinoma in a thyroglossal duct cyst; diagnostics and treatment]M F J van der Heide, L H E Karssemakers, J P de Boer, et al.
Infection and Immunity|October 1, 1993
Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation patternJ P de Boer, A A Creasey, A Chang, et al.
Current Treatment Options in Oncology|November 19, 2013
Current treatment options for local residual nasopharyngeal carcinomaS D Stoker, J N A van Diessen, J P de Boer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2005
Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patientsR L M Haas, Ph Poortmans, D de Jong, et al.
Pageof 4